Formulation and Evaluation of VCAM-1-Targeted Methotrexate Lipid Nanoparticles for Rheumatoid Arthritis Therapy
MTX@LNP-PVCAM-1 combines passive and active targeting, delivering MTX efficiently to inflamed sites and reducing toxicity. This approach enhances anti-inflammatory effects in AIA rats, offering a potential strategy for low-toxicity RA treatment.
Authors
- Weiliang Ye (ORCID: https://orcid.org/0000-0002-9904-5502)
- Jiangfan Han
- Jianmei Jing
- Zhenhua Tong (ORCID: https://orcid.org/0000-0002-2178-2457)
- Xuegang Sun (ORCID: https://orcid.org/0000-0001-6581-0520)
- Yang Hua (ORCID: https://orcid.org/0000-0001-8058-1527)
- Li Ye
- Jiajun Wang (ORCID: https://orcid.org/0000-0002-7554-370X)
- Ren Na (ORCID: https://orcid.org/0009-0003-7895-7566)
- Xiaofeng Yuan (ORCID: https://orcid.org/0009-0005-1042-0660)
- Guangbin He
Institutions
- People's Liberation Army No. 150 Hospital (CN)
- General Hospital of Shenyang Military Region (CN)
- Chinese People 's Liberation Army No. 85 Hospital (CN)
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2025-09-01
- DOI
- https://doi.org/10.2147/ijn.s532163
- Citations
- 3
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 5.00